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Xenotropic murine leukaemia virus-related virus (XMRV) is a recently described retrovirus which has been claimed to infect
humansand cause associated pathology. Initially identiﬁed in the US in patients with prostate cancer and subsequently in patients
with chronicfatigue syndrome,doubt nowexists thatXMRV isa humanpathogen.Westudied the prevalence ofgenetic sequences
of XMRV and related MuLV sequences in human prostate cancer, from B cell lymphoma patients and from UK blood donors.
Nucleic acid was extracted from fresh prostate tissue biopsies, formalin-ﬁxed paraﬃn-embedded (FFPE) prostate tissue and FFPE
B-cell lymphoma. The presence of XMRV-speciﬁc LTR or MuLV generic gag-like sequences was investigated by nested PCR. To
control for mouse DNA contamination, a PCR that detected intracisternal A-type particle (IAP) sequences was included. In
addition, DNA and RNA were extracted from whole blood taken from UK blood donors and screened for XMRV sequences
by real-time PCR. XMRV or MuLV-like sequences were not ampliﬁed from tissue samples. Occasionally MuLV gag and XMRV-
LTR sequences were ampliﬁed from Indian prostate cancer samples, but were always detected in conjunction with contaminating
murine genomic DNA. We found no evidence of XMRV or MuLV infection in the UK blood donors.
1.Introduction
In 2006, a new gammaretrovirus, xenotropic murine leukae-
mia virus-related virus (XMRV),was discoveredby the Viro-
chip analysis in prostate cancer tissue from patients homozy-
gous for an RNase L mutation [1]. In these patients, the
innate antiviral defence RNase L pathway is defective; hence,
these patients are likely to be susceptible to viral infection
and a population more likely to ﬁnd a novel virus with
disease association in. When a second US study found that
6% of all prostate cancer patients, independent of RNase
L mutations, were infected with the virus, thus broadening
the population at risk [2], interest in XMRV intensiﬁed.
However, subsequent studies from the USA [3, 4]a n da l l2 Advances in Virology
European studies [5–7] failed to conﬁrm the presence of
XMRV in prostate tissue. More recently it has been suggested
that XMRV detection in prostate tissue in the US could be
related to the speciﬁcity and conditions of the PCR used [8].
In 2009, Lombardi and colleagues reported the presence
of XMRV proviral DNA in peripheral blood leucocytes from
3.7% of healthy controls and 67% of patients with chronic
fatigue syndrome (CFS) [9]. The detection rate by PCR
ampliﬁcation of XMRV proviral DNA subsequently reduced
the estimated CFS prevalence to 7%, with the explanation
that RNA extraction and cDNA synthesis had been required
to achieve the 67% prevalence originally reported [10]. Lo
and colleagues (2010) using predominantly archival material
from patients with CFS detected a high prevalence (86.5%)
of pMuLVs. These are similar to, but constitute a diﬀerent
group from, the xenotropic endogenous MuLVs to which
XMRV belongs [11]. However, questions were raised about
how these data were generated [12], and a number of other
studies have failed to demonstrate a link between XMRV or
pMuLV infection and CFS [13–19].
The causes of B-cell lymphoma are not fully understood
[20], but the clinical and epidemiological characteristics
are suggestive of the involvement of an infectious agent
[21]. Several viruses [22, 23] have been linked to the
risk of B-cell lymphoma, most notably EBV [24–26], and
retroviruses are implicated in animal leukaemias. Retroviral
integration could cause somatic DNA changes leading to
clonal expansion ofB cells resulting in leukaemia as has been
previously described for adult T-cell leukaemia (ATL) and
HTLV-1 [27].
The geographical discrepancy of XMRV and pMuLV
prevalence remains unexplained. To explore this further, we
have tested a variety of tissues from diverse populations;
prostate cancer (PC) formalin-ﬁxed paraﬃn-embedded
(FFPE) tissue from Japan and India, fresh prostate tissue
samples received from the Urology Clinic at St Mary’s
Hospital, London, and peripheral blood from English blood
donors.
A series of recent papers [28–31]h a v ed e m o n s t r a t e dt h e
easewithwhich specimens canbecontaminatedwithmurine
DNAsequences.To control for this, all tissue specimens were
tested by PCR speciﬁc for intracisternal A particle (IAP), a
retrotransposon present in multiple copies (∼1000) within
the mouse genome [32].
2.Methodsand Materials
2.1. Samples and Nucleic Acid Isolation. Prostate biopsies
were collected from 55 patients admitted to the Urology
Department, St. Mary’s Hospital, London, UK to undergo
routinebiopsyforprostatecancerscreening.Allpatientsgave
writteninformed consentfortheirtissuetobebankedforthe
purposes of research (ethics number 99/CCC/166, August
1999). The DNA was extracted using the QIAamp DNA
mini kit (Qiagen,Crawley, UK)following the manufacturer’s
instructions.
B-cell lymphoma samples were provided by Professor
Kikkiri Naresh, Centre for Pathology, Hammersmith Hos-
pital, London, UK. The DNA from 10 Diﬀuse Large B-cell
Lymphoma (DLBLC) patients was extracted from FFPE
tissues of lymph nodal or extranodal diﬀuse large B-cell
lymphoma using the DNeasy Blood & Tissue Kit (Qiagen).
Brieﬂy, two 15μm sections were cut and transferred to
1.5mL Eppendorf tubes. Blades were changed between sam-
ples to avoid cross-contamination. Sections were deparaf-
ﬁnised with xylene and ethanol, rehydrated, and incubated
with proteinase K and lysis buﬀer in a shaking water bath at
55◦C overnight and the extraction was completed according
to the manufacturer’s instructions.
Twenty FFPE prostate specimens including 10 prostate
cancer (PC) and 10 benign prostatic hyperplasia (BPH)
samples were supplied by Professor Ganesh Golpalakrishnan
of Vedanayagam Hospital, RS Puram, Coimbatore, India
and sixteen specimens from Dr. Takahiro Kimura of the
Department of Urology, The Jikei University School of
Medicine,Japan. FromtheIndian blocks,two10μMs e cti o n s
were extracted with the QIAamp DNA FFPE tissue kit
(Qiagen), according to the manufacturer’s instructions. The
Japanese samples were provided presliced on glass slides.
Random anonymous whole-blood samples were obtai-
ned from the Donation Testing Department at the National
Health Service Blood and Transplant (NHSBT) Centre at
Colindale, London, UK. Plasma minipools were similarly
obtained from NHSBT. All blood and plasma samples were
extracted on a Qiagen MDx Biorobot and eluted with 80μL
of Qiagen buﬀer AVE.
2.2. XMRV, MuLV, and Control Nested PCR. Samples were
tested for the presence of XMRV and MuLV proviral DNA
using nested PCR, as described previously [14]. Brieﬂy, we
used a set of primers that encompasses the 24bp deletion
in the XMRV gag leader region, originally described to dis-
tinguish XMRV as a new human virus, along with a second
set of primers reﬂecting a sequence conserved amongst most
MuLVs. The positive control for the XMRV and MuLV PCRs
was plasmid VP62 [1]. The PCR method has been shown to
besensitive enoughtopickuponecopyofXMRVVP62plas-
mid in a background of 500ng DNA [28]. As a control for
sample addition and PCR inhibition, primers to the human
beta-globin (hBG) gene were used. DNA extracted from
LNCaP (human prostate cancer cells) was used as a positive
control for human beta globin. To control forcontamination
of samples with murine DNA,primers speciﬁc to mouse IAP
were used as described previously [28]. The positive control
for IAP was DNA from the McCoy cell (murine ﬁbroblast
cells, ECAAC90010305).Inall PCRs, atleast 6“no template”
controls were set up. All PCR products were visualised on
Ethidium Bromide-stained 2% agarose gels.
2.3. XMRV, MuLV, and Control Real-Time PCRs for Blood
Donor Studies. Real-time PCR was performed as detailed in
Table 1. For the proviral DNA analysis, 10μLo ft h en u c l e i c
acid extract were analysed separately in three individual
quantitative PCRs (Q-PCRs).
2.3.1. XMRV Q-PCR and Internal Control. Samples were
testedbyQ-PCRforXMRV,asdescribedbyMcCormicketal.
[33]a n dm o d i ﬁ e da sd e t a i l e di nTable 1.I naQ - P C Rt oAdvances in Virology 3
Table 1 :D e t a i l so fP C R su s e dt ot e s tb l o o ds a m p l e .
Sample tested PCR Target Primers and probes Cycles (N)R e a g e n t s
540 DNAs from whole
blood XMRV Taq Man gag XMRV Probe, F, R 60 Qiagen
QuantiTect Probe kit
540 DNAs from whole








540 DNAs from whole




600 NAs from whole
blood
400 NAs from plasma
minipools
XMRV/pMuLV RT









The TaqMan assay conditions were 15min at 95◦C (15secs 95◦C, 1min 60◦C) ×N cycles. 400nM concentrations of primers, and 200nM probes were used
in all the TaqMan assays with the exception of the CDC MuLV Taq Man where the concentration of each probe was 100nM and the PDH TaqMan where the
primer concentrations were 50nM.
control for the extraction eﬃciency and ampliﬁcation inhi-
bition coextracted soil-borne cereal mosaic virus (SBCMV)
plasmid DNA was used, (5.4 × 106 copies were added to
the 33mL of Qiagen lysis buﬀer AL used for extracting
96 samples on the MDx Biorobot). This reaction was as
described by Ratti et al. [34]. The primer sequences for
this reaction were SBCWMVCPF (5 -CAC TCA GGA CGG
TGA CGA GAT-3 ), SBCWMVCPR (5 -GTG ATA CTG TGA
GTC TGG TGA TGA TTT-3 )a n dp r o b eSBWMV237Fa (5 
JOE-TTT TGT GAC CTT GGA GGT GAG GCA GTT ATG-
BHQ1-3 ).
2.3.2. Q-PCR for Quantiﬁcation of Human DNA. The input
ofhuman DNAineach extract was measured byaQ-PCRfor
the Pyruvate dehydrogenase (PDH) gene. Primers used PDH
Taq 1 (5 -TGA AAG TTA TAC AAA ATT GAG GTC ACT
GTT-3 ),PDHTaq 2(5 -TCCACAGCCCTCGAC TAACC
-3 )w i t hp r o b ePDHP (5 -VIC-CCC CCA GAT ACA CTT
AAG GGA TCA ACT CTT AAT TGT-Tamra-3 ). Positive
control for this reaction was a dilution series of human male
DNA (Applied Biosystems, Warrington, UK, Catalogue no.
4312660). The XMRV Q-PCR results were validated when
the PDH threshold cycle (Ct) value was greater than the
mean Ct minus 3 SD, and the SBCMV control was greater
than the mean Ct minus 2 SD. Samples invalid on either
control were excluded from the analysis.
2.4. Detection of Gag Sequences by Nested PCR in Blood
Donors. Nuclease-free water (Severn Biotech, Kiddermin-
ster, UK) was used throughout for the cDNA and PCR
mix preparations and as no-template controls. Nucleic acid
extracts were tested by nested PCR using the gag primers as
described by Lombardi et al. [9]a n dL oe ta l .[ 11], but using
Applied Biosystems Taq Gold LD PCR enzyme (Table 1)t o
overcometheproblemoffalse positivesthathavearisen from
the use of Invitrogen Taq Polymerase [30].
2.5. QRT-PCR Ampliﬁcation of XMRV/pMuLV in Blood
Donors. An XMRV/pMuLV gag QRT-PCR assay described
by Loand colleagues[11]butmodiﬁed todetectthepMuLVs
was used to test nucleic acid from whole blood, plasma, and
from plasma minipools. Further details of all QPCR and
QRT-PCR reactions are listed in Table 1. The primers for this
reaction were F3 (5 -ACC GTT TGT CTC TCC TAA AC-
3 )a n dR4 (5 -AGG GTA AAG GGC AGA TCG-3 ), with
probe P2 (5 -Fam-CCG ACA GCT CCC GTC CTC CCG-
Tamra-3 ). Nuclease-free water (Severn Biotech) was used
throughout for the RT-PCR mix preparations and as no
template controls. RT-PCR was performed in a total volume
of 50μL, containing 1x Qiagen QuantiTect RT-PCR buﬀer
and primers, and probes as detailed in Table 1.S y n t h e s i s
conditions were 50◦C for 30mins, followed by 95◦Cf o r
15mins and 45 cycles of 95◦C for 15secs 60◦Cf o r1 m i n .
Twenty μl of nucleic acid was analysed in a QRT-PCR which
multiplexed the XMRV/pMuLV TaqMan with the internal
c o n t r o lT a q M a nr e a c t i o n( B r o m em o s a i cv i r u s( B M V ) )[ 35].
The BMV RNA was added to the Qiagen AL lysis buﬀer
and co-extracted with the sample. A sample was valid if the
BMV Ct value was greater than the mean Ct minus 2 SD.
Samples invalid on the BMV control were excluded from the
analysis. The sensitivity of this QRT-PCR was determined as
150 RNA copies/mL (75 viral particles/mL) by calculation
from the observed frequency of negatives using the Poisson
distribution.
3.Results
3.1. XMRV Detection in Tissue Samples by Nested PCR. A
representative stained gel following nested PCR is shown
in Figure 1. For routine analysis, 0.11pg of plasmid DNA
(representing approximately 7000copies/PCR) was used as
positive control for XMRV and MuLV. All samples were
positive for hBG sequences by PCR. The sensitivity of the
IAP PCR has been shown previously to detect as little as
0.0011pg DNA in a background of 500ng DNA [28]. The
results are summarised in Table 2(a). No evidence of XMRV
or MuLV was found in any of the FFPE prostate tissue
samples from Japan or the fresh prostate tissues from the4 Advances in Virology
Table 2
(a) Ampliﬁcation from fresh and FFPE tissuesby nested PCR
Fresh prostate tissue Japan samples Indian samples LCBCL samples
Number of cancerous samples 16/55 16 10/20 10
Number of noncancerous samples (unknown status) 18/55 (21/55) 0 10/20 0
Mean age (range) unknown unknown 72 (62–85) 43 (27–83)
Beta globin + 55/55 16/16 20/20 10/10
XMRV + 0 0 2/20 0
MuLV + 0 0 4/20 0
IAP + 0 0 5/20 0
mtDNA + nd nd 2/10 nd
(b) Speciﬁc PCR results from Indian samples
Indian sample number Cancer status PCR result using speciﬁc primers
β-globin IAP mtDNA MLV gag XMRV LTR
6489c/10 cancer + + + + +
5383c/10 cancer + + − ++
5406a3/10 cancer + + −− −
2896c/10 BPH + + + + −
5349c/10 cancer + + − + −






Figure 1: lane 1: MWM; lanes 2–4: β-globin PCR on LNCaP
DNA template 1st round product, 2nd round product, and no-
template control; lanes 5–7: XMRV LTR PCR on VP62 plasmid
DNA template 1st round product, 2nd round product, and no-
templatecontrol;lanes8–10:MuLVgag PCRonVP62plasmidDNA
template 1st round product, 2nd round product, and no-template
control; lanes 11-12: IAP PCR on McCoy cell DNA template and
no-template control.
UK. Of the 20 Indian samples, four (20%) produced a PCR
signal with the MuLV gag primers (three prostate cancer,
one benign prostatic hyperplasmia) and of these, 2/4 were
positive with XMRV LTR primers (both prostate cancer).
The IAP PCR was applied to the same samples to see if
the positive signal was due to mouse DNA contamination.
All MuLV/XMRV ampliﬁcation was concordant with IAP
ampliﬁcation, except for one prostate cancer sample which
was positive for IAP without MuLV/XMRV ampliﬁcation.
Conﬁrmation of murine DNA contamination was achieved
using PCR primers speciﬁc to mouse mitochondrial DNA
(mtDNA). Although this PCR has been shown to be less
sensitive than IAP PCR [28], 2/20 of the Indian samples
(one prostate cancer, one benign prostatic hyperplasia) were
positiveformtDNA.Inbothofthesesamples,IAPandMuLV
gag sequences were ampliﬁed. Additionally, one was positive
for XMRV (detailed in Table 2(b)).
No evidence of MuLV or XMRV sequences was discov-
ered in the DLBCL samples and none of the DCBCL samples
gave an IAP speciﬁc product.
3.2. XMRV Detection in Whole Blood by Real-Time PCR.
XMRV proviral DNA was not ampliﬁed from whole-blood
extracts derived from 540 donors. The average DNA input
for each ampliﬁcation was 93,000 cells (approx 0.56μg).
Detection of XMRV/MuLV RNA was undertaken on a
further 600 donors and 400 plasma minipools, derived from
19,200 individual donations. All samples tested negative for
XMRV and MuLV sequences.
4.Discussion
Using highly sensitive PCRs with primers that detect XMRV
and primers that detect MuLV-like sequences, no proviral
DNA was detected in any of the prostate cancer samples
independently of murine DNA contamination. This served
to conﬁrm our previous studies in which FFPE prostate
tissue was tested and XMRV/MuLV sequences failed to be
ampliﬁed [28]. Here we haveadded further datato show that
no XMRV or MuLV-like sequences can be detected in fresh
UK prostate tissue or in prostate cancer samples collected
from Japan. Samples from India showed evidence of MuLV
and XMRV sequences when viral genomic sequences were
ampliﬁed by nested PCR. However, this was concordantwith
murinegenomicDNAcontaminationdetectedusingprimersAdvances in Virology 5
to IAP. IAPs are retrotransposons present at the level of
around 1000 copies per mouse genome [30]. Thus, IAP PCR
represents a highly sensitive detection method for murine
DNA.Althoughthesamplesize wassmall (n = 10),wefound
noevidencetosuggestthatXMRVmight beinvolvedinother
cancers, such as diﬀuse large B-cell lymphoma.
It was reported last year that XMRVhad been detected in
greater than 60% of 50 samples from English blood donors
[36]. In contrast, we found no evidence of XMRV or pMuLV
in any of 540 whole-blood samples from unselected NHSBT
donors nor were we able to detect MuLV-like sequences in
either the DNA from whole blood or cDNA prepared from
the plasma minipools from donors in England. There are
three possible explanations for this. Firstly, there are no
MuLVinfectionsinblooddonorsinEngland. Secondly,there
are MuLV infections, but that the assays used failed to detect
them, either dueto sensitivity or sequencevariation. Thirdly,
thereare MuLVinfections, buttheprevalenceis toolowto be
detected in the sample sizes tested.
R e s e a r c hi n t ot h ep r e s e n c eo fM u L V si nt h eh u m a n
population is contentious, given discrepant ﬁndings [37–
39]. Contamination from sequences contained in apparently
XMRV-positive samples, ampliﬁed products, or plasmids
has been suggested as a reason for the ﬁnding of MuLVs
in human samples [30, 40]. A study of XMRV in patients
with CFS or chronic immunomodulatory conditions, using
InvitrogenPlatinum Taq (IPT),reported a gag sequence with
>99% homology to a mouse endogenous retrovirus [19].
This was designated as contamination, although the paper
failed to speculate on the source of this sequence. Sato and
colleagues (2010) recently reported ﬁnding predominantly
RNA sequences, related to a pMuLV, in IPT containing
reagents [30]. Another study concluded that the detection
of MuLV-related sequences in human samples could be due
to contamination with mouse DNA, most likely contained
in various laboratory reagents [29]. We have demonstrated
that murine sequences can be present in prostate sections,
resulting in false positive detection of XMRV [28]. A
phylogenetic overview concludedthat the proviral sequences
present in the genome of 22Rv1 cell line were ancestral to
the published XMRV sequences [31]; ﬁnally, it has been
shown that the mapping of integration sites of XMRV in
prostatecancertissues, thoughttounequivocallyconﬁrmthe
existence of XMRV in clinical samples, was at least partially
contaminant derived [41], further emphasising the ease with
which contamination can occur.
The sources of contamination are still to be fully
elucidated. However, given that most retroviral laboratories
have worked with MuLV or MuLV-derived vector systems,
or at least used murine reagents, it is essential that suﬃcient
appropriate controls are included in all PCRs.
The absence of MuLVs from all the samples analysed
in this study, where there was no concomitant detection
of murine genomic sequences, adds weight to the growing
body of data questioning the evidence for murine retrovirus
infection of humans [42]. It is always challenging to prove a
negative result,butit islikelythatXMRVwill beaddedto the
long list of RNA rumour viruses [43].
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